Clinical Trial Update: Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic, safety and immunogenicity study comparing the new process CMAB015 with Cosentyx in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)
• New Process CMAB015

Snippet

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Conditions: Psoriasis | Phase 1 | Status: NOT_YET_RECRUITING